Abstract
Background: No specic antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19).The aim of this study was to summarize the antiviral activities of remdesivir against SARS-CoV-2, the causative agent of COVID-19. We present our observations on remdesivir use. Methods: In a retrospective case control study total 74 patients of moderate to severe covid 19 infection admitted to Dhiraj hospital were enrolled. Out of total 74 patients, 37 were given remdesivir assigned as group A and 37 patients were not given remdesivir assigned as group B. Data was collected from the case record form and analyzed with respect to inammatory markers, mortality, length of ICU stay and days on ventilator support. Results: Out of 74 moderate to severe RT PCR positive Covid 19 patients, 37 patients were in remdesivir group and others were in non remdesivir group. Mean age was 55.08 + 8.98 years and 22 were male in remdesivir group. Statistically signicant improvement was noted with ESR, CRP and Sr.LDH only. Other laboratory parameters (TLC, NLR, D-Dimer, and Sr.Ferrtin) showed minor improvement only (p value =>0.05).Less mortality was observed with remdesivir treatment, along with ICU stay and less days on ventilator therapy without any safety concerns. Conclusion: Remdesivir use along with standard therapy had showed signicant improvement in terms of clinical, laboratory parameters and recovery in patients with moderate to severe Covid 19 infection.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
